Tern Plc secures extension on £120,000 loan balance

TERN

Tern Plc (LON:TERN), the investment company specialising in supporting high growth, early-stage, disruptive Internet of Things technology businesses, has announced that the repayment date of the loan facility agreement originally announced on 12 June 2023 has been extended, with the agreement of the Loan provider, to 11 September 2026.  The Board considers that the extension gives the Company greater negotiating flexibility in relation to funding the future capital requirements of its investee companies.  Since being entered into the Loan has been varied twice previously, as announced on 4 September 2024 and 15 September 2025.

The Company has agreed to make a payment of £38,432.88 to the Loan provider as a partial repayment of the outstanding Loan balance and accrued interest, plus a Loan extension fee of £6,000. Following these payments £120,000 will remain outstanding under the Loan and this amount, plus accrued interest at a rate of 1.00% per calendar month, will be repayable by the Company on or before 11 September 2026.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Peptide drug development expands beyond GLP-1

GLP-1 success is widening interest in peptide drug development, with the next phase focused on proving clinical value across new therapeutic areas.

Tern Plc announces 90% take-up of Open Offer

Tern Plc has received valid acceptances for 50.9 million Open Offer Shares, representing approximately 90% of the shares available. The fully underwritten offer will raise approximately £509,368 before expenses, with admission of the new shares expected on 24 September 2026.

Talking Medicines moves to capture pharma demand for better patient intelligence

Tighter US pharma advertising rules could increase demand for patient intelligence, supporting the relevance of Talking Medicines’ DrugVoice platform.

Tern portfolio company Talking Medicines launches ‘Intent to Prescribe’ DrugVoice application

Talking Medicines has launched a new DrugVoice application combining its Message Resonance Score™ with near-real-time point-of-care data to help pharmaceutical companies assess links between HCP message alignment and prescribing intent.

Device Authority targets secure digital infrastructure for smart ports

Device Authority's Smart, Green Port Blueprint shows how secure device management can support the wider rollout of connected infrastructure across modern ports.

Talking Medicines highlights strategic signals emerging across the GLP-1 consumer market

GLP-1 consumers are increasingly weighing access, affordability, quality, clinical oversight and treatment support, creating new strategic considerations across the wider life sciences market.

Search